Cytokinetics Announces Publication of Phase II Evidence of Effect Study of CK-2017357

Both patients and investigators perceived a dose-dependent benefit of CK-2017357 as measured by global impression of change. Maximum voluntary ventilation and submaximal handgrip endurance also improved.

Categories: Research News, Treatments  |  Tags: ALS, ALS medical care, ALS research, ALS treatments, amyotrophic lateral sclerosis, Andrew A. Wolff, Bob Stehlin, CK-2017357, Clinical Trial Publication of CK-2017357 in Amyotrophic Lateral Sclerosis, CY 4025, Cytokinetics, fast skeletal muscle troponin activator, FDA Fast Track designation ALS, Jeremy M. Shefner, Phase II, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Upstate Medical University at the State University of New York  |  No comments